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Abstract: The exposure of phosphatidylserine (PtdS) is a common molecular
marker for both apoptosis and necrosis and enables the simultaneous
detection of these distinct modes of cell death. Our aim was to develop a
radiotracer based on the PtdS-binding activity of the C2A domain of
synaptotagmin I and assess 99mTc-C2A-GST (GST is glutathione Stransferase) using a reperfused acute myocardial infarction (AMI) rat model.
Methods: The binding of C2A-GST toward apoptosis and necrosis was
validated in vitro. After labeling with 99mTc via 2-iminothiolane thiolation,
radiochemical purity and radiostability were tested. Pharmacokinetics and
biodistribution were studied in healthy rats. The uptake of 99mTc-C2A-GST
within the area at risk was quantified by direct γ-counting, whereas
nonspecific accumulation was estimated using inactivated 99mTc-C2A-GST. In
vivo planar imaging of AMI in rats was performed on a γ-camera using a
parallel-hole collimator. Radioactivity uptake was investigated by region-ofinterest analysis, and postmortem tetrazolium staining versus
autoradiography. Results: Fluorescently labeled and radiolabeled C2A-GST
bound both apoptotic and necrotic cells. 99mTc-C2A-GST had a radiochemical
purity of >98% and remained stable. After intravenous injection, the uptake
in the liver and kidneys was significant. For 99mTc-C2A-GST, radioactivity
uptake in the area at risk reached between 2.40 and 2.63 %ID/g (%ID/g is
percentage injected dose per gram) within 30 min and remained plateaued
for at least 3 h. In comparison, with the inactivated tracer the radioactivity
reached 1.06 ± 0.49 %ID/g at 30 min, followed by washout to 0.52 ±
0.23 %ID/g. In 7 of 7 rats, the infarct was clearly identifiable as focal uptake
in planar images. At 3 h after injection, the infarct-to-lung ratios were 2.48 ±
0.27, 1.29 ± 0.09, and 1.46 ± 0.04 for acute-infarct rats with 99mTc-C2AGST, sham-operated rats with 99mTc-C2A-GST, and acute-infarct rats with
99m
Tc-C2A-GST-NHS (NHS is N-hydroxy succinimide), respectively. The
distribution of radioactivity was confirmed by autoradiography and histology.
Conclusion: The C2A domain of synaptotagmin I labeled with fluorochromes
or a radioisotope binds to both apoptotic and necrotic cells. Ex vivo and in
vivo data indicate that, because of elevated vascular permeability, both
specific binding and passive leakage contribute to the accumulation of the
radiotracer in the area at risk. However, the latter component alone is
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insufficient to achieve detectable target-to-background ratios with in vivo
planar imaging.
Keywords: C2A domain, synaptotagmin I, apoptosis, necrosis, myocardial
infarction

Noninvasive imaging of cell death has important diagnostic and
prognostic predictive potentials. Collectively, the underlying pathologic
cause of many degenerative diseases can be attributed to the interplay
of different modes of cell death. Among the 2 dominant forms of cell
death, apoptosis has gained much attention in modern medicine not
only because of the deleterious consequences of its deregulation but
also as an opportunity for therapeutic intervention1–5. The active
process of apoptosis is an intracellular, energy-dependent event6,7.
Once committed, the execution phase of apoptosis involves a
proteolytic cascade catalyzed by caspases and is accompanied by
distinct molecular markers8–11. In contrast, necrosis is a form of
passive cell death recognized by swelling and plasma membrane
damage. The characterization of apoptosis and necrosis is likely to
dictate the development and implementation of novel imaging
technologies.
Acute myocardial infarction (AMI) involves both forms of cell
death, although the exact extent of each remains controversial
because of variations in animal models and detection methods12. It has
been generally accepted that necrosis occurs at the central ischemic
zone, whereas apoptosis is more prevalent in the periphery within the
area at risk. In addition, apoptotic cell death involves not only
cardiomyocytes but also nonmyocytes to a comparable degree,
including vascular endothelium, macrophages, and blood cells13.
Although conventionally AMI has been regarded as a primarily necrotic
condition, infarct imaging using necrosis-avid agents has achieved a
certain degree of success by targeting necrotic markers, such as
calcium deposit, histone, and myosin epitope14. The better
understanding of different forms of cell death has presented the
opportunity to detect multiple, if not all, forms of cell death as a single
comprehensive category and, thus, has provided the potential
advantage of being more likely to reflect the true extent of irreversible
myocardial damage.
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A common molecular marker for both apoptosis and necrosis is
the exposure of phosphatidylserine (PtdS), and its presence can
facilitate target-specific imaging of cell death. In viable cells, PtdS is
strictly a constituent of the inner leaflet of the plasma membrane. The
asymmetry of the lipid bilayer is maintained by the actions of energydependent enzymes, including aminophospholipid translocase and
floppase15. During apoptosis, the inhibition of translocase and floppase
is accompanied by the activation of scramblase, and the redistribution
of phospholipids across the bilayers is facilitated15. As a result, PtdS
becomes exposed onto the cell surface. In necrotic cells, the passive
rupture of the plasma membrane renders intracellular components,
including PtdS, accessible to extracellular milieu. As one of the major
phospholipid components of the plasma membrane, PtdS provides an
abundant molecular marker for the detection of both apoptosis and
necrosis once it becomes accessible.
The C2A domain of synaptotagmin I binds to negatively charged
phospholipids in membranes, including PtdS, in a calcium-dependent
manner16. C2A labeled with fluorochromes and contrast agents has
allowed detection of cell death using fluorescent and MRI techniques,
respectively17,18. The imaging applications of another protein that binds
PtdS, annexin V, have also been well documented in a wide range of
animal models and clinical studies19–22. Meanwhile, derivatives of
annexin V continue to evolve in the search for improved binding and
pharmacokinetic profiles23,24.
The aim of this study was 2-fold: development of a technetiumbased PtdS-binding molecular probe for detecting apoptosis and
necrosis and characterization of the imaging tracer within the context
of AMI. To date, the uptake of radiolabeled annexin V in acute and
chronic infarct has been described in animal models and in human
patients25,26, but key questions remain unresolved. AMI is
characterized by a multiplicity of cellular and physiologic changes, not
only including various forms of cell death but also markedly elevated
vascular permeability and increased interstitial space27. In fact, these
structural changes have become the foundation for delineating infarct
areas with MRI using apparently nonspecific contrast agents27,28.
Therefore, the presence of PtdS-binding radiotracers in the infarct
region does not necessarily warrant PtdS interaction but also can be
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associated with nonspecific leakage of the tracer across the vascular
boundary and diffusion into the interstitial space. Here, our
investigation was designed to characterize one such radiotracer, 99mTclabeled C2A, for its distribution within the area at risk. The C2A was
overexpressed and labeled in the form of C2A-GST (GST is glutathione
S-transferase) fusion protein. The inclusion of GST only moderately
increases molecular weight but greatly reduces the probability of
chemical modification in the vicinity of the PtdS-binding site on C2A.
We show that (a) fluorescently labeled C2A-GST specifically binds to
both apoptotic and necrotic cells in vitro, (b) the fusion protein can be
stably labeled with 99mTc at a reasonably high radiochemical yield and
purity through thiolation using 2-iminothiolane, (c) a high
accumulation of 99mTc-C2A-GST in the area at risk is attributed to both
specific binding and passive distribution, and (d) 99mTc-C2A-GST
uptake allows noninvasive visualization of AMI in a rat model using
single-photon planar imaging, whereas passive leakage alone was
insufficient for such detection.

Materials and Methods
C2A-GST was overexpressed in Escherichia coli and purified as
described previously16. The protein was dialyzed in phosphate-buffered
saline (PBS) (pH 7.4), lyophilized, and stored at −20°C.

Fluorescein Isothiocyanate (FITC) Labeling of C2A-GST
and Cell Assays
Three hundred microliters of C2A-GST (2 mg/mL) in PBS were
mixed with 2.33 μL of FITC (12 mg/mL in dimethyl sulfoxide [DMSO])
and gently shaken for 3 h at room temperature. C2A-GST-FITC was
purified using a Sephadex G-25 column equilibrated with PBS.
Apoptosis was induced in Jurkat cells (American Type Culture
Collection) at a density of 5 × 106 cells/mL with 3.5 μmol/L
camptothecin (Sigma) for 3 h. C2A-GST-FITC and propidium iodide
(PI) were added to final concentrations of 1 and 5 μg/mL, respectively.
The sample was analyzed by 2-color flow cytometry. In parallel, the
same cells were analyzed with commercial annexin V-FITC (Sigma; 1
μg/mL) and PI (5 μg/mL) according to the manufacturer's instructions.
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To test whether both C2A-GST and annexin V recognize the
same apoptotic or necrotic cells, C2A-GST was labeled with Alexa Fluor
680 (AF680; Molecular Probes). Specifically, 250 μL of C2A-GST (2
mg/mL; 100 mmol/L NaHCO3, 60 mmol/L NaCl, pH 8.2) were mixed
with 12.4 μL of AF680 (1 mg/mL in methanol). After 1 h at room
temperature while shielded from light, the conjugate was purified
using G-25 Sephadex chromatography. C2A-GST-AF680 was
incubated, in the direct presence of annexin V-FITC, with treated
Jurkat cells and analyzed with flow cytometry to detect C2A-GST–
positive cells (red) and annexin V–positive cells (green).

Tc Labeling of C2A-GST

99m

C2A-GST was labeled with 99mTc in a 2-step process29.
Specifically, 200 μL of C2A-GST (2 mg/mL) solution in PBS were mixed
with 2.96 μL of 2-iminothiolane (10 mg/mL in DMSO) and incubated at
37°C for 1 h. Then 500 μL of
in 0.9% NaCl were added to a
stannous glucoheptonate mixture (80 μg stannous chloride and 8 mg
sodium glucoheptonate) and incubated at room temperature for 10
min under N2. Four hundred microliters of 99mTc-glucoheptonate were
mixed with 200 μL of thiolated C2A-GST and incubated for 30 min at
room temperature. 99mTc-C2A-GST was purified using Sephadex G-25
chromatography.
The radiochemical purity (RCP) of 99mTc-C2A-GST and the
presence of 99mTc-colloid were analyzed by instant thin-layer
chromatography (ITLC-SG; Gelman Sciences) using 2 solvent systems
as the mobile phase: saline and NH3·H2O/alcohol/H2O (1:2:5, v/v/v).
The stability of 99mTc-C2A-GST was assessed by incubating
Tc-C2A-GST (10 μL, 0.2 mg/mL) in 500 μL saline, rat serum, or
whole blood at room temperature. The RCP was measured by ITLC at
1, 2, 4, and 24 h with corrections for decay. The degree of thiolation
was estimated using Ellman's reagent30. For control purposes, inactive
99m
Tc-C2A-GST was produced by reacting with 2 mmol/L sulfo-Nhydroxy succinimide (NHS) acetate for 15 min at room temperature
and purified.
99m
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In Vitro Binding Assays
About 1 μg of 99mTc-C2A-GST was incubated with 500 μL of
apoptotic or untreated cells (5 × 105) in 15 mmol/L N-(2hydroxyethyl) piperazine-N′-(2-ethanesulfonic acid) (HEPES), 120
mmol/L NaCl, 2 mmol/L CaCl2, pH 7.4. A parallel sample was prepared
using 99mTc-C2A-GST-NHS as the control. To separate cell-bound from
free 99mTc-C2A-GST, the mixture was centrifuged at 1,000g for 2 min
through 100 μL of silicon oil. After removing the aqueous supernatant
and oil layer, the tip of each tube that contained the pellet was cut off
and its radioactivity was measured by γ-counting.
Binding specificity after radiolabeling was evaluated using a
competition assay. Specifically, 99mTc-C2A-GST (78 nmol/L) was
incubated with 5 × 105 camptothecin-treated Jurkat cells in the
presence of unlabeled C2A-GST from 15.9 to 7,830 nmol/L. The
radioactivity that remained bound to the cells was calculated as a
percentage of that without competition and plotted against the
concentration of unlabeled C2A-GST. The 50% inhibitory concentration
(IC50) at this particular experimental condition was the concentration
of unlabeled C2A-GST required to reduce the binding of 99mTc-C2A-GST
by 50% (B50).

Blood Half-Life and Biodistribution Studies in Normal
Rats
Animal procedures were conducted following National Institutes
of Health guidelines and with institutional approval. Blood clearance of
99m
Tc-C2A-GST or 99mTc-C2A-GST-NHS was studied in anesthetized
healthy male Sprague–Dawley rats (8- to 10-wk old; n = 5). 99mTcC2A-GST (46 μg) was injected via a left femoral vein catheter. Ten
microliters of blood were sampled from a right femoral artery catheter
at 0.5, 5, 10, 15, 20, 30, 40, 60, 120, and 180 min after injection. The
blood radioactivity was measured by γ-counting.
For biodistribution, each rat was injected with 3.7 MBq of 99mTcC2A-GST via the femoral vein. One group of 5 rats was sacrificed at
10, 30, 60, and 180 min after injection. The radioactivity uptake was
measured for blood, heart, lung, spleen, liver, kidney, stomach, small
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intestine, large intestine, bone, muscle, fat, and skin by γ-counting
using an energy window between 120 and 160 keV. Data are
expressed in terms of percentage injected dose per gram or per organ
± SD (%ID/g ± SD or %ID/organ ± SD). Blood, muscle, and bone
were assumed to represent 7%, 40%, and 10% of body weight,
respectively. The percentages of fat and skin of whole-body weight are
unavailable and, thus, are not included as %ID/organ.

Uptake Study in Rat Model of AMI
This procedure is to quantify the absolute tracer uptake in the
area at risk versus viable myocardium at different times after
injection. Here, we used an acute infarct model with 18 min of
ischemia followed by 2 h of reperfusion. With this model we have
confirmed the presence of acute infarction using triphenyl tetrazolium
chloride (TTC) staining. Acute infarct models using a short duration of
ischemia have also been reported elsewhere28,31.
For each anesthetized rat, after tracheotomy and intubation,
respiration was maintained using a rodent respirator. After
thoracotomy, the left descending coronary artery was ligated for 18
min using a 6.0 suture at 1 mm below the left atrial appendage. After
reperfusion, the loose suture was left in place until sacrifice, when an
area-at-risk measurement was made. 99mTc-C2A-GST (∼7.4 MBq) was
injected via the femoral vein at 2 h of reperfusion. A group of 4 rats
was sacrificed at 10, 30, 60, and 180 min after injection. The left
descending coronary artery was reoccluded at 30 s before sacrifice and
2 mL of Evans Blue (2% in PBS, w/v) were injected into the femoral
vein to stain perfused myocardium. The myocardium devoid of Evans
Blue was considered as the area at risk. After dissecting and weighing
the heart tissues, tracer uptake in the area at risk and normal
myocardium was determined separately by γ-counting. The results are
expressed as %ID/g ± SD. To quantify nonspecific uptake, 99mTc-C2AGST-NHS was studied using an identical protocol.
To investigate whether the uptake of 99mTc-C2A-GST is
associated with the treatment of ischemia or reperfusion per se, the
above experiment was repeated with 5 min of ischemia followed by 2 h
of reperfusion.
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Histology
Terminal deoxynucleotidyl transferase–mediated dUTP nick-end
labeling (TUNEL) was performed according to the manufacturer's
protocol, using 10-μm short-axis cryosections of the heart. At least
3,500 nuclei were counted from random fields within the area at risk
or in the normal region, under a magnification of ×400. The apoptotic
index was calculated in terms of TUNEL-positive nuclei as a percentage
of total nuclei. For electron microscopy (EM), specimens from the area
at risk and the normal myocardium were fixed in 4%
paraformaldehyde and 0.5% glutaraldehyde for 24 h at 4°C. The
tissues were dehydrated, sectioned, and mounted on carbon grids for
transmission EM.

In Vivo Imaging of AMI in Rat Model
Reperfused ischemic injury was created in rats as described. To
examine the background tracer uptake, we included sham-operated
rats with identical surgery except for coronary occlusion. Either 99mTcC2A-GST or 99mTc-C2A-GST-NHS was injected via the femoral vein at a
dosage of ∼37 MBq, and anterior planar images of each rat in prone
position were acquired using an Infinia (GE Healthcare) γ-camera and
parallel-hole collimator with a 15% energy window centering at 140
keV. A reference radiation source was positioned on the left side of the
animal. The field of view was 22.5 × 22.5 mm with a 512 × 512
matrix. Each image was acquired with 1 million counts at 0, 40, 80,
120, 160, and 200 min after injection. Heart-to-lung ratios were
estimated using region-of-interest analysis.

Autoradiography
After the rat was sacrificed, the heart was harvested and quickly
rinsed in saline. About 2 mL of 0.5% TTC in HEPES buffer (w/v) was
infused retrograde into the aorta to stain the entire myocardium. After
15 min of incubation at 37°C, the heart was fixed in 4% formaldehyde.
Short-axis sections of the heart with a thickness of ∼500 μm were cut
and exposed to Kodak BMX MS film overnight at −80°C. After the film
was developed, each corresponding slice was fixed overnight in 1%
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formaldehyde in PBS (v/v). Digitized autoradiography and histology
section images were inspected visually.

Results
The fusion protein has a molecular weight of 39,687 Da, with
346 amino acids, of which 130 are from C2A and 201 are from GST.
The flexible linker sequence contains 15 residues, in which a thrombin
cleavage site is included. There are 14 Lys and no Cys in C2A and 19
Lys and 4 Cys in GST, with the flexible linker peptide containing
neither residue.

FITC Labeling of C2A-GST and In Vitro Studies
The fluorescein-to-protein ratio of C2A-GST-FITC was estimated
to be 1.1 ± 0.2. To test the binding activity for apoptotic and necrotic
cells, C2A-GST-FITC was incubated with control or camptothecintreated Jurkat cells and analyzed using flow cytometry. As shown in
Figures 1A and 1B, distinct cell populations were detected as viable
(V), apoptotic (A), and necrotic (N). In addition, a presumably early
apoptotic (EA) population was identified with intermediate fluorescent
intensity. These cells appear to be at a transitional state toward fully
developed apoptosis or necrosis; yet they are negative for PI. A nearly
identical flow cytometric profile was obtained in a parallel staining
study using a commercial annexin V staining kit, which is regarded as
a gold standard for in vitro cell viability analysis (Figs. 1C and 1D).
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Figure 1. Flow cytometry of control (A and C) and camptothecin-treated (B and D)
Jurkat cells, with FITC-labeled C2A-GST (A and B) and annexin V (C and D) and
costaining with PI and double staining using C2A-GST-AF680 and annexin V-FITC (E).
Four distinct populations identified by C2A-GST-FITC are illustrated in B, including
viable (V), early apoptotic (EA), apoptotic (A), and necrotic cells (N).

To further evaluate the binding specificity of C2A-GST, double
staining of camptothecin-treated Jurkat cells was performed with
coincubation of C2A-GST-AF680 (red) and annexin V-FITC (green) and
analyzed by dual-color flow cytometry. Simultaneous uptake of both
red and green fluorescence was seen in each positive cell (Fig. 1E),
whereas the viable cells were negative. There was clearly an absence
of single positive cells for either color. The 2 fluorochromes were
selected to minimize emission spectra overlap, where the emission
wavelength of AF680 is near-infrared and FITC is in the green
fluorescence range (Fig. 1E).
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99m

Tc Labeling of C2A-GST

According to Ellman's method, each molecule of C2A-GST
contains an average of 2.87 and 7.15 thiols before and after
iminothiolation, respectively. The radiochemical yield and purity data
of the nonthiolated and thiolated C2A-GST are as follows: Before gelfiltration purification, the RCP values for the native and thiolated
protein are 12.5% and 72.8%, respectively. After gel-filtration
purification, the values are 88.4% and 98.9%, respectively. Under
identical labeling conditions, the radiochemical yield is enhanced ∼4fold with thiolation. The stability of the labeled protein was tested in
saline, rat whole blood, and rat serum. The protein retained the
radiolabel over a 24-h period as determined by ITLC (Table 1).
TABLE 1 Stability Test for
Fluid

Tc-C2A-GST

99m

0h

1h

2h

4h

24 h

Saline

99.53

99.53

99.12

98.70

98.42

Rat serum

99.53

96.42

95.70

93.40

91.32

Rat whole blood

99.53

90.85

90.77

90.08

89.17



99mTc-C2A-GST

was incubated with saline, rat serum, or whole blood for 1, 2,
4, and 24 h. RCP was determined using ITLC.

In Vitro Binding Assays
The uptake and binding specificity of 99mTc-C2A-GST were
evaluated using camptothecin-treated Jurkat cells as the binding
target. For 5 × 105 cells after 3 h of stimulation and incubation with
99m
Tc-C2A-GST, the radioactivity uptake was 9.12-fold ± 0.6 higher
than that of the nontreated viable control population. In comparison,
99m
Tc-C2A-GST-NHS showed a 1.88 ± 0.04 times difference under
identical experimental conditions. In the presence of increasing
concentrations of unlabeled C2A-GST, the uptake of radioactivity in
treated Jurkat cells was competitively inhibited, with a well-defined
sigmoid pattern. Using 5 × 105 treated cells and 80 nmol/L 99mTc-C2AGST, the IC50 of unlabeled C2A-GST was 90.01 ± 11.12 nmol/L (n =
3). However, the competition profile was absent when unlabeled C2AGST was replaced with bovine serum albumin, GST, or C2A-GST-NHS.
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Biodistribution and Blood Clearance
The distribution of radioactivity after intravenous injection of
Tc-C2A-GST in healthy rats is summarized as a function of time
(Fig. 2). The most prominent organs of uptake include the liver and
kidneys, suggesting hepatic and renal clearance. The presence of
radioactivity in the spleen, bones, and lungs was significant, with the
latter reflecting the blood-pool activity. In contrast, there is relatively
low uptake in viable myocardium, gastrointestinal tract, adipose
tissues, skeletal muscles, and skin. There is no indication that the
radiotracer crosses the blood–brain barrier. A low thyroid uptake
suggests that there was minimal dissociation of the radioisotope from
the labeled protein. The blood clearance of 99mTc-C2A-GST was typical
for a macromolecule of comparable size, with an estimated half-life of
the fast clearance phase at <15 min (n = 5). No toxicity effect was
observed at the current dosage.
99m

Figure 2. Biodistribution of 99mTc-C2A-GST in healthy rats at 10, 30, 60, and 180 min
after injection (n = 5). Radioactivity uptake is shown in terms of %ID/g (A)
and %ID/organ (B).
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Uptake Study in Rat Model of AMI
The uptake of radioactivity in the area at risk versus normal
myocardium after 99mTc-C2A-GST or 99mTc-C2A-GST-NHS injection in
rats was quantified as a function of time using direct γ-counting. As
summarized in Figure 3, the radioactivity level in the area at risk after
99m
Tc-C2A-GST injection reached 1.91 ± 0.59 %ID/g within the first 10
min after injection and plateaued between 2.40 and 2.63 %ID/g after
30 min. The uptake in normal myocardium was 0.21 ± 0.01 %ID/g at
10 min, with a gradual washout to 0.09 ± 0.04 %ID/g at 180 min. In
comparison, radioactivity uptake from 99mTc-C2A-GST-NHS reached as
high as 1.06 ± 0.49 %ID/g at 30 min, presumably due to nonspecific
vascular leakage, followed by washout to 0.52 ± 0.23 %ID/g at 180
min. The distribution of 99mTc-C2A-GST-NHS in normal myocardium
over time was similar to that of 99mTc-C2A-GST. According to
above %ID/g measurements, the target-to-background ratio between
the area at risk and normal myocardium is 30.4 for 99mTc-C2A-GST,
whereas the ratio is 6.5 for 99mTc-C2A-GST-NHS at 180 min after
injection. TTC staining demonstrates the presence of infarct tissues
within the area at risk, indicating the occurrence of extensive necrosis.
This transition was in parallel with the elevation of apoptotic index
from 0.27% to 4.70%. Short stimulation with 5 min of ischemia
followed by reperfusion caused no significant uptake of 99mTc-C2A-GST
in the area at risk compared with viable myocardium at 1 h after
injection.
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FIGURE 3. Radioactivity uptake, in terms of %ID/g, in rats in area at risk (AR) and in
normal (VI) myocardium at 10, 30, 60, and 180 min after intravenous injection of
99mTc-C2A-GST and 99mTc-C2A-GST-NHS (n = 4).

In Vivo Imaging of AMI in Rat Model
The biodistribution and uptake data were confirmed by in vivo
planar imaging. Prominent hepatic uptake was seen in all cases
immediately after radiotracer injection, followed by an increase in
signal in the kidneys and bladder over time. As shown in Figure 4A,
with the clearance of blood-pool and lung activities, a hot-spot uptake
was visible as early as 40 min after injection, consistent with the
location of the left anterior region of the left ventricle in infarct animals
injected with 99mTc-C2A-GST. In 7 of 7 rats with an acute infarct, the
signal became more focal and distinct over time. In contrast, neither
infarct animals injected with 99mTc-C2A-GST-NHS nor sham-operated
rats injected with 99mTc-C2A-GST showed significant tracer uptake in
the left ventricle region (Fig. 4A). At 3 h after injection, the infarct-tolung ratios were 2.48 ± 0.27, 1.29 ± 0.09, and 1.46 ± 0.04 for acute
infarct rats injected with 99mTc-C2A-GST (n = 7), sham-operated rats
injected with 99mTc-C2A-GST (n = 3), and acute infarct rats injected
with 99mTc-C2A-GST-NHS (n = 3), respectively. The presence of
radioactivity in the area-at-risk region in rats injected with 99mTc-C2AGST was also confirmed by autoradiography and TTC staining (Fig.
4B).
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FIGURE 4. (A) In vivo single-photon planar imaging of sham-operated rat (Control)
and rat with infarct at 0, 40, 80, 120, 160, and 200 min after intravenous injection of
99mTc-C2A-GST. Arrow indicates site of the infarct. (B) Corresponding TTC staining and
autoradiography images.

Discussion
This study evaluated a molecular probe, 99mTc-C2A-GST, and
addressed the dynamic uptake profile using quantitative and
semiquantitative methods in a rat model of reperfused AMI. The
radiotracer targets PtdS as a common marker for both apoptosis and
necrosis and detects cell death as a single comprehensive category.
C2A-GST could be readily labeled with fluorochromes or a
radioisotope. When fluorescently labeled, apoptosis and necrosis
binding activity of the conjugates was comparable to that of annexin
V. When coincubated with chemically treated cells in vitro, the 2 PtdSbinding proteins associate with apoptotic and necrotic cells, suggesting
that the 2 molecular probes interact with a shared molecular marker,
presumably PtdS. C2A and annexin V are 2 structurally distinct
proteins, whereas their binding activity is somewhat similar in that
they interact with anionic phospholipids in a calcium-dependent
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fashion16,31−35. In contrast to annexin family members that assume
predominantly helical structures, C2A is a compact β-sandwich31–35.
Given the importance of developing target-specific molecular probes
for apoptosis and necrosis, a greater structural diversity should lead to
a better chance of discovering isoforms or derivatives that generate
favorable binding and pharmacokinetic properties. Although a direct
and quantitative comparison between the 2 PtdS-binding proteins is
beyond the scope of this study, it warrants further investigation in
terms of binding activities, structural properties, and potentials for in
vivo applications.
For radiolabeling using 99mTc, thiolation of the fusion protein was
essential, although there are native cysteine residues in native C2AGST. According to Ellman's method, the native protein contains an
average of 2.87 thiols per molecule, whereas the conjugate has an
average of 7.15. These data indicate that the conjugation introduced
an average of 4.3 thiols per molecule. Although, according to
sequencing there are 4 Cys residues in native C2A-GST, there appears
to be a discrepancy between the measured and the actual number of
thiol groups in the native protein (2.87 by Ellman's test vs. 4 from
sequencing). This could be explained by the 3-dimensional structure of
GST (EC 2.5.1.18; Schistosoma japonicum), where the side chain of
Cys-169 is facing away from the protein surface while the thiol groups
of Cys-85, Cys-138, and Cys-178 appear to be exposed and easily
accessible. Thus, the outcome of Ellman's test could have reflected the
orientation and accessibility of thiol groups to the colorimetric reagent,
5,5′-dithio-bis-(2-nitrobenzoic acid), dissolved in the aqueous
environment. The lack of efficient 99mTc incorporation before
iminothiolation suggests that the endogenous thiols do not form
favorable chelating sites for the radioisotope. The radiolabeled C2AGST has a relatively high RCP and good radiostability. After
radiolabeling, 99mTc-C2A-GST appeared to have retained its binding
activity. In vitro, significantly elevated uptake of the radiotracer was
detected in camptothecin-treated Jurkat cells compared with that of
the control. In addition, the fact that the binding of 99mTc-C2A-GST
was reversible in the presence of competing unlabeled C2A-GST
indicates that both forms of C2A-GST specifically interact with the
same well-defined binding targets in treated cells and that the binding
specificity of 99mTc-C2A-GST was well preserved.
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Successful development of an infarct-avid imaging agent not
only relies on an understanding of cell death processes but also is
critically dependent on characterization of specific as well as passive
distribution of such tracers. Vascular hyperpermeability associated
with ischemic challenge have been well documented. This brings up
the issue of diffusive leakage of a radiotracer into the interstitial space
in parallel with specific uptake. To the best of our knowledge, the
characterization of specific versus passive components has not been
thoroughly documented to date. According to this study, accumulation
of the inactivated tracer in the area at risk peaked at ∼30 min after
injection and accounted for as much as 1 %ID/g, followed by a gradual
washout. The data can be interpreted as extravasation of the tracer
through compromised vascular structures and the diffusive distribution
in interstitial space. During the initial period after injection, a high
blood-pool concentration of the tracer favors infiltration into the area
at risk. But with blood clearance, the shifting intravascular
concentration drives the equilibrium toward a reversal and
redistribution process as seen from the washout pattern. The timing
and the degree of nonspecific uptake here are consistent with existing
literature on ischemia- or reperfusion-induced vascular permeability
changes measured using radiolabeled macromolecules and highmolecular-weight MR contrast agents27,28. Although the binding of
99m
Tc-C2A-GST-NHS with unknown targets in the area at risk could not
be completely ruled out, such interactions, if any, are likely to be
relatively weak and transient as the tracer is washed out with declining
blood-pool activity. On the other hand, the active molecular probe,
99m
Tc-C2A-GST, appears to be sequestered in the area at risk. This
uptake of 99mTc-C2A-GST is likely to consist of both specific and
nonspecific components. The fact that the uptake level plateaued after
30 min may be a reflection of 2 dynamic components between a
continuous accumulation due to specific binding and the vascular
permeability-dependent diffusion equilibrium. The uptake of 99mTcC2A-GST positively correlates with ischemia or reperfusion challenge
that results in infarction and elevation of apoptotic index in the area at
risk, whereas short stimulation with 5 min of ischemia followed by
reperfusion causes no significant uptake of 99mTc-C2A-GST in the area
at risk.
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The in vivo imaging results were consistent with ex vivo uptake
studies and demonstrated the feasibility of noninvasive imaging of
acute infarction in small-animal models. When calibrated against the
marker, which represents 0.5 %ID, region-of-interest analysis
indicates that the lesion uptake at the heart correlates with 0.7 to
1 %ID. In healthy rats, 99mTc-C2A-GST clears from the blood pool in a
well-defined profile. Meanwhile, the inactivated 99mTc-C2A-GST-NHS
did not produce a target-to-background ratio that allows recognition of
the infarct from the planar images.

Conclusion
With the synthesis and characterization of 99mTc-C2A-GST we
describe the dynamic uptake of a PtdS-binding molecular probe in the
area at risk. The data indicate that both specific binding and passive
leakage due to vascular hyperpermeability contribute to the
accumulation of the radiotracer at the area at risk. However, the latter
component alone is insufficient to achieve detectable target-tobackground ratios with in vivo planar imaging. On the basis of this
study, C2A and its derivatives hold promise in becoming suitable
radiopharmaceuticals for the noninvasive imaging of apoptosis and
necrosis.
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